Protalix Biotherapeutics Stock Today
| PLX Stock | USD 1.69 0.03 1.81% |
Performance18 of 100
| Odds Of DistressLess than 42
|
Protalix Biotherapeutics is trading at 1.69 as of the 25th of November 2024; that is 1.81 percent increase since the beginning of the trading day. The stock's open price was 1.66. Protalix Biotherapeutics has about a 42 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. Equity ratings for Protalix Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of December 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of May 1998 | Category Healthcare | Classification Health Care |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company has 73.63 M outstanding shares of which 3.1 M shares are at this time shorted by investors with about 22.71 days to cover. More on Protalix Biotherapeutics
Moving against Protalix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Protalix Stock Highlights
| President CEO | Dror Bashan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Point Loma Resources Ltd, PHELIX N.V., Protalix Biotherapeutics Inc, Przetworstwo Tworzyw Sztucznych Plast-Box S.A., Pyrolyx AG] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, VN 30, VN100, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProtalix Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Protalix Biotherapeutics' financial leverage. It provides some insight into what part of Protalix Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protalix Biotherapeutics (PLX) is traded on NYSE MKT Exchange in USA. It is located in Science Park, Karmiel, Israel, 2161401 and employs 208 people. Protalix Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 124.44 M. Protalix Biotherapeutics runs under Biotechnology sector within Health Care industry. The entity has 73.63 M outstanding shares of which 3.1 M shares are at this time shorted by investors with about 22.71 days to cover.
Protalix Biotherapeutics has about 17.11 M in cash with (1.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Protalix Biotherapeutics Probability Of Bankruptcy
Ownership AllocationProtalix Biotherapeutics owns a total of 73.63 Million outstanding shares. Protalix Biotherapeutics holds 14.53 pct. of its outstanding shares held by insiders and 5.2 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Protalix Ownership Details
Protalix Biotherapeutics Historical Income Statement
Protalix Stock Against Markets
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.